A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors. Piha-Paul, S. A., Nagpal, S., Weise, A. M., Braiteh, F. S., Chen, C., Huang, C., Liu, W., Hu, Y., Yang, Z., Tsai, K. K. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772000654